Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.
about
Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its DerivativesCancer immunotherapy: the beginning of the end of cancer?Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer DrugsThe Promise of Preventive Cancer VaccinesThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentSerial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironmentPan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cellsProspective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapyImproved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.Dendritic cell generation and CD4+ CD25high FOXP3+ regulatory t cells in human head and neck carcinoma during radio-chemotherapy.Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.The immunologic aspects of poxvirus oncolytic therapyProspective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosisPredictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingTumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patientsA safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancerThe effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.Combination immunotherapy approaches.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Licensing Adaptive Immunity by NOD-Like Receptors.Various ways to improve whole cancer cell vaccines.Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.γδ T cell therapy for the treatment of non-small cell lung cancer.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.Adapting conventional cancer treatment for immunotherapy.Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy.NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
P2860
Q26738330-D4AD00C7-6CF9-4941-80FB-516E2DBDFE93Q26752277-2292DA5A-58DB-42B1-9CB8-370F401A5ABBQ26781522-50CF5336-8E76-4E0B-BC43-E2A042C67E56Q26783742-DCF02EA2-CD69-4B43-A6A5-1088248B4318Q27022789-BB667B6E-1BD0-4B86-889D-7FECC1E1A521Q27335748-632B9805-9B6E-4328-B697-DC9834AFDFB5Q28485258-749A2ECE-BD98-4AEC-8C89-82A6FCB5E099Q35060987-D7BAB3D8-8297-4E3F-A007-EEEC6223CEBAQ35218520-A4C3CC10-67E3-4789-BE15-21329FEF41F8Q35789363-B01111EF-4FB3-4BCA-AF4A-149238D4C4D8Q35963926-B558FF29-5ED6-4BBE-AD43-E7CF051AF898Q36023202-97B78D77-3E4E-4C54-830E-FD49AC7266A6Q36115128-21DAB4C2-CCCC-4ED9-955A-90DFA96E0A87Q36579336-3BF155B9-05A6-4376-A073-DEB97E02B459Q36673469-BBD56B0B-E609-42B8-9014-158C5283EA80Q36763988-6823532B-CF32-4A3A-A66D-918F236028E7Q37232002-E8644CC8-3D8B-4FCC-AA3B-F085C9CE2162Q37299843-1584A135-44B1-47BF-8A44-9C64E510D977Q37323046-E66A2F86-40BD-4FB2-BD1E-737A8138989CQ37531844-829D0F9A-22D3-43D5-8FAB-1F5A2312DD76Q37728232-4117C9D0-9C5A-4B0D-B94B-99CCB9C63DB0Q37800934-56570FC6-5867-4541-AA4C-484BF6CF5255Q37866150-7E62435E-D7E4-4534-AFCD-943C594C025CQ38037492-3DE0A1D6-E973-47E4-B578-68AC971D7569Q38168904-ED6F82DC-D5F3-422E-B296-75B108E292B4Q38177270-3D7EB46C-336F-4052-A9F1-E7BFA0A5E89DQ38206582-3A6CE30B-2AD8-49F1-8710-F7D8AC46DA41Q38246950-97B417E7-8B9B-484F-A23F-745922AF08B6Q38261921-CEB1280E-8293-4BFF-8B26-0FB8D1E628BAQ38366904-8D7E6B74-F18C-4A01-879D-40F4F9CB7AD6Q38390100-D6818B2C-C4F4-4721-86C3-ECEB0E5DB65EQ38447992-7C4B510E-7D6C-428B-9355-1D46C741C1E3Q38548889-93921ACA-A70E-459F-8468-F5CC1AAD5992Q38748185-58843295-99E5-4643-8D40-C603B04A1A92Q38847914-99A555F9-2F62-46EF-AE94-72DFE3EE9CF1Q38848219-0E6BBD2B-3B15-4E0F-B591-B233D12AE7ABQ38971333-AEF06921-6A1A-4E7F-B3DB-0A3F5451321BQ39234393-FD098B03-FA9E-443B-888A-7C09759CC29DQ39356108-B74DC83C-215C-419B-B640-E6AB2B7F1040Q39674459-752C12F8-2325-4D5B-9C72-FAC0DFA6D7E3
P2860
Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@en
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@nl
type
label
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@en
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@nl
prefLabel
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@en
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@nl
P2860
P50
P1476
Cancer chemotherapy: not only ...... juvant for antitumor immunity.
@en
P2093
Cédric Ménard
Florence Bouyer
P2860
P2888
P304
P356
10.1007/S00262-008-0505-6
P577
2008-03-28T00:00:00Z